Hormonal
Adenosine acts as a primary sleep-promoting factor by inhibiting wake-active cholinergic neurons in the basal forebrain via A1 receptors and stimulating sleep-active neurons in the ventrolateral preoptic area (VLPO) via A2 receptors, with extracellular concentrations increasing during wakefulness and decreasing during sleep.
Your brain naturally produces adenosine during wakefulness, which builds up to create sleep pressure. This process is mediated by specific receptors in the basal forebrain and VLPO. While caffeine blocks this signal to keep you awake, understanding this mechanism explains why sleep deprivation leads to higher adenosine levels and why sleep is necessary to clear it.
The mechanism of sleep promotion by adenosine is based upon a withdrawal of the stimulatory activity of forebrain the cholinergic and non-cholinergic basal neurons... adenosine may cause disinhibition of these neurons by inhibiting the GABAergic neurons presynaptically... Alternatively, adenosine may directly stimulate sleep-active neurons via A2 excitatory receptors.
Why this rating
The paper cites microdialysis studies, receptor knockout mice, and consistent cross-species findings.
Source
Biochemical regulation of non-rapid-eye-movement sleep
James M. Krueger · Frontiers in bioscience · 2003
DOI 10.2741/1033
More from this paper
- Prostaglandin D2 (PGD2) is a major sleep-promoting eicosanoid produced by leptomeninges and choroid plexus that stimulates sleep by eliciting adenosine release from arachnoid cells, which then acts on the ventrolateral preoptic area (VLPO).Strong
- Delta sleep-inducing peptide (DSIP), uridine, oxidized glutathione, and muramyl peptides were identified as early 'sleep factors' through transfer experiments, but they lack a determined physiological sleep regulatory role compared to adenosine and PGD2.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →